Patent · US Active

Anti-CD137 antibodies and uses thereof

US11505615B2 · kind B2 · utility

0Cited by

7References

11Claims

0Family size

Assignee

LYVGEN BIOPHARMA HOLDINGS LIMITED · CN

Inventors

Jieyi Wang · Lake Bluff, US
Yi-Ting Wu · Shanghai, CN

Key dates

Filing date	Dec 4, 2018
Grant date	Nov 22, 2022
Priority date	—
Expiry date	Feb 8, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are agonistic anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.